Rankings
▼
Calendar
VRTX
Vertex Pharmaceuticals Incorporated
$125B
Q4 2018 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$870M
+33.5% YoY
Gross Profit
$748M
85.9% margin
Operating Income
$128M
14.7% margin
Net Income
$1.6B
178.2% margin
EPS (Diluted)
$5.97
QoQ Revenue Growth
+10.9%
Cash Flow
Operating Cash Flow
$315M
Free Cash Flow
$299M
Stock-Based Comp.
$79M
Balance Sheet
Total Assets
$6.2B
Total Liabilities
$1.8B
Stockholders' Equity
$4.4B
Cash & Equivalents
$2.7B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$870M
$652M
+33.5%
Gross Profit
$748M
$568M
+31.8%
Operating Income
$128M
$126M
+1.6%
Net Income
$1.6B
$101M
+1440.0%
Revenue Segments
ORKAMBI
$315M
36%
SYMDEKO/SYMKEVI
$294M
34%
KALYDECO
$259M
30%
Geographic Segments
UNITED STATES
$677M
59%
Non-US
$332M
29%
Europe
$142M
12%
← FY 2018
All Quarters
Q1 2019 →
VRTX Q4 2018 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena